期刊文献+

左西孟旦治疗失代偿心衰合并肾功能不全患者的疗效观察 被引量:11

Clinical efficacy of levosimendan in patients with decompensated heart failure complicated with renal insufficiency
下载PDF
导出
摘要 目的观察左西孟旦治疗失代偿心衰合并肾功能不全患者的疗效。方法回顾性分析本科2013年7月至2015年5月住院治疗的63例失代偿心衰患者(男性41例,女性22例),患者按肾功能损害程度分为2组:肾功能重度损害组(L1组)33例[GFR:15~<60 m L/(min·1.73 m^2)]和肾功能轻度损害组(L2组)30例[GFR:60~89 m L/(min·1.73 m^2)],输注左西孟旦治疗。比较、分析治疗后1、3、7、30 d患者N-末端脑钠肽前体(N-terminal pro-B-type natriuretic peptide,NT-pro-BNP)、左心室射血分数(left ventricular ejection fraction,LVEF)、肾小球滤过率(glomerular filtration rate,GFR)的变化。结果 2组间治疗前除GFR外,其余基线指标差异无统计学意义(P>0.05);2组治疗后NT-pro-BNP 1、3、7 d较基线显著下降(P<0.05),LVEF 3、7 d较基线显著上升(P<0.05);2组间治疗前后NT-proBNP和LVEF差异无统计学意义(P>0.05);2组治疗后GFR 1、3、7 d较基线显著上升(P<0.05),其中L1组GFR 30 d仍较基线显著上升(P<0.05);L1组治疗后GFR改变量(△GFR)显著高于L2组(P<0.05)。结论失代偿心衰合并肾功能不全患者应用左西孟旦,能够改善心肾功能,对肾功能显著下降患者的肾功能改善幅度更大、持续时间更长。 Objective To determine the efficacy of levosimendan in patients with decompensated heart failure complicated with renal insufficiency. Methods Clinical data of 63 decompensated heart failure patients hospitalized in the department of cardiology from July 2013 to May 2015 were collected and retrospectively analyzed. These patients were divided into 2 groups according to the renal injury extent: L1 group [glomerular filtration rate( GFR) : 15 - 〈60 m L /( min ·1. 73 m^2),n = 33]and L2 group [GFR:60 - 89 m L /( min·1. 73 m^2),n = 30],and all the patients were treated by infusion of levosimendan. Nterminal pro-B-type natriuretic peptide( NT-pro-BNP),left ventricular ejection fraction( LVEF),and GFR were compared and analyzed before treatment and on 1,3,7,and 30 d after treatment. Results Before treatment,there were no significant differences in the baseline data between the 2 groups except GFR( P〉0. 05). On 1,3 and 7 d after treatment,NT-pro-BNP were significantly decreased in the 2 groups( P〈0. 05),and on 3 and 7 d after treatment,LVEF was significantly higher than the baseline value. Before and after treatment,NT-pro-BNP and LVEF showed no significant differences between the 2 groups( P〉0. 05).On 1,3 and 7 d after treatment,GFR was significantly increased in the 2 groups( P〈0. 05),and on 30 d after treatment,GFR of group L1 was still increased( P〈0. 05). After treatment,the level of △GFR( GFR change) was significantly higher in the L1 group than in the L2 group. Conclusion Levosimendan can improve heart and kidney functions in the patients with decompensated heart failure complicated with renal insufficiency,and the improvement of renal function is greater and longer in the patients with severe renal insufficiency.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2016年第8期897-900,共4页 Journal of Third Military Medical University
基金 重庆市渝中区科技计划项目(20130146)~~
关键词 左西孟旦 心力衰竭 肾功能不全 肾小球滤过率 levosimendan heart failure renal insufficiency glomerular filtration rate
  • 相关文献

参考文献19

  • 1Barbici I, Hedman A, Ewaldsson C A. Use of levosimendan in patients with heart failure in different settings: case reports and treatment guidance[J]. Heart Lung Vessel, 2015, 7(2): 143-150. 被引量:1
  • 2Yilmaz M B, Grossini E, Silva-Cardoso J C, et al. Renal effects of levosimendan: a consensus report[J]. Cardiovasc Drugs Ther, 2013, 27(6): 581-590. 被引量:1
  • 3Bragadottir G, Redfors B, Ricksten S E. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study[J]. Crit Care Med, 2013, 41(10): 2328-2335. 被引量:1
  • 4Hou Z Q, Sun Z X, Su C Y, et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction[J]. Cardiovasc Ther, 2013, 31(2): 108-114. 被引量:1
  • 5Zorlu A, Yucel H, Yontar O C, et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function [J]. Arq Bras Cardiol, 2012, 98(6): 537-543. 被引量:1
  • 6Francis G. Acute decompensated heart failure: the cardiorenal syndrome[J]. Cleve Clin J Med, 2006, 73(Suppl 2): S8-S13, S30-S33. 被引量:1
  • 7Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies [J]. Crit Care Med, 2012, 40(2): 634-646. 被引量:1
  • 8Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods[J]. Intensive Care Med, 2011, 37(2): 290-301. 被引量:1
  • 9王雷,崔亮,魏嘉平,李广平,齐国先,郝玉明,王文志,李慧敏,刘俊,姜东炬,张玉东.静脉注射左西孟旦治疗重度失代偿性心力衰竭患者的疗效分析[J].中华心血管病杂志,2010,38(6):527-530. 被引量:57
  • 10Grossini E, Molinari C, Pollesello P, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs [J]. J Pharmacol Exp Ther, 2012, 342(2): 376-388. 被引量:1

二级参考文献10

  • 1Nieminen MS,Bohm M,Cowie MR,et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J,2005,26:384-416. 被引量:1
  • 2Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dubutamine in severe lowoutput heart failure (the LIDO study):a randomised donble-blind trial.Lancet,2002,360:196-202. 被引量:1
  • 3Moiseyev VS,Poder P,Andrejevs N,et al.Safety and efficacy of a novel calcium sensitizer,levosimendan,in patients with left ventricular failure due to an acute myocardial infarction.A randomized,placebo-controlled,double-blind study (RUSSIAN).Eur Heart J,2002,23:1422-1432. 被引量:1
  • 4Cleland JG,Ghosh J,Freemantle N,et al.Clinical trials update and cumulative meta-analyses from the American College of Cardiology:WATCH,SCD-HeFT,DINAMIT,CASINO,INSPIRE,STRATUS-US,RlO-Lipids and cardiac resynchronisation therapy in heart failure.Eur J Heart Fail,2004,6:501-508. 被引量:1
  • 5McMurray JJ,Pfeffer MA.Heart failure.Lancet,2005,365:1877-1889. 被引量:1
  • 6Lloyd-Jones DM,Larsen MG,Leip EP,et al.Lifetime risk for developing congestive heart failure:the Framingham Heart Study.Circulation,2002,106:3068-3072. 被引量:1
  • 7Sharma M,Tserlink JR.A rational approach for the treatment of acute heart failure:current strategies and future options.Curr Opin Cardiol,2004,19:254-263. 被引量:1
  • 8Dec GW.Acute decompensated heart failure:the shrinking role of inotropic therapy.J Am Coil Cardiol,2005,46:65-67. 被引量:1
  • 9Nieminen MS,Akkila J,Hasenfuss G,et al.Hemodynamic and neurohumoral effects of continuous infusion of levesimendan in patients with congestive heart failure.J Am Coll Cardiol,2000,36:1903-1912. 被引量:1
  • 10Nijhawan N,Nicolosi AC,Montgomery MW,et al.Levosimendan enhances cardia performance after cardiopulmonary bypass:a prospective,randomized placebo-controlled trial.J Cardiovasc Pharmacol,1999,34:219-228. 被引量:1

共引文献56

同被引文献88

引证文献11

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部